Panel discussion about Artificial Intelligence tools for personalized medicine from the perspective of financing and clinical practice at NCPHM from Poiana Brașov, Romania
An excellent panel discussion took place at the 8th edition of the National Conference on Pharmacoeconomics and Health Management (www.cnfms.ro), held on 14-16th of October 2021 at Poiana Brașov, Romania, with invited members of the CLL-CLUE consortium, international experts and representatives of payer organizations:
– Sigrid S. SKANLAND, PhD – Oslo University Hospital, Norway
– Carsten Utoft NIEMANN, MD, PhD, Associate Professor – Rigshospitalet, Copenhagen University Hospital, Denmark
– Adrian GHEORGHE, expert, former President of NHIH, Romania
– Prof. Pharm. Dr. Tomas TESAR, Slovakia
– Prof. Zoltan KALÓ, Syreon Research Institute, Hungary
– László LORENZOVICI, MD, Syreon Research Romania
The theme of this discussion was “Artificial Intelligence tools for personalized medicine from the perspective of financing and clinical practice in onco-hematology”, with a focus on the CLL-CLUE project.
During the panel discussion the following questions were debated:
- How to integrate an AI assisted tool into the clinical therapeutic protocols? How to change the practice of defining such protocols for AI assisted tools?
- How to set financial protocols in concordance to the AI assisted tool? How to handle situations where financial constraints and optimal therapies are in conflict?
- How to integrate the reimbursement of genetic / other specific tests required for the decision-making algorithm to the health care financing systems?
- What are the most important differences in the implementation of AI assisted tools between Western and Eastern European countries?
June 2021: CLL-CLUE patient representative meeting
It was our pleasure and honor to have the first meeting with our two patient representatives on the 21st of June 2021 to discuss how to improve communication with patients, how to meet their expectations on use of data and biobank samples to improve treatment outcome, and how to support their participation in future clinical trials.
The role of patient representatives
The role of the patient representative is to ensure that the views of patients, caregivers and families are taken into consideration when planning/developing services. This will help facilitate the “patient voice” being heard throughout the wider organization, whenever decisions that affect healthcare are made.
The CLL-CLUE patient representatives
The CLL-CLUE project has two patient representatives. The first representative has more than 10 years of experience with the role, and finds it more and more meaningful. She emphasized the importance of using lay language that the patient can understand when informing about research projects and clinical trials. “The better the patient understands the study, the easier it will be for the patient to give informed consent”, she said. The second patient representative agreed with this. He also pointed to the role of the physician as a guide to help the patient navigate in shared decision-making. The aim of CLL-CLUE is to implement precision medicine for CLL patients. Establishing a dialogue with the patients about their needs and concerns ensures that this aim remains in focus.
January 2021: The official newsletter (no. 5 / 2021) of the ERAPerMed published the Results of the Joint Transnational Call 2020.
Please find details about CLL-CLUE project on page 4